Contact Us

Contact Us

Please contact us below with any questions

info@quadratech.co.uk

+44 (0)33 3321 2371

Side Contact
×
Sign up to our newsletter Click Here
quadratech Logo
{{ toggleHam ? 'CLOSE' : 'MENU' }}
Next Day & International Delivery
Competitive Pricing
Over 30 Years Experience
Based In The UK

Featured Products

Our Product Ranges

Recieve our latest news

Sign up to our newsletter

Our Company

 

With over 30 years of trading experience, Quadratech Diagnostics Limited has always been and remains committed to providing the highest quality state-of-the-art medical diagnostic and research products. Since the company was founded in 1990, we have expanded to encompass the following main areas: HaemostasisAntigens, Antibodies and ToxinsRapid and POC TestsParasitology and Veterinary.

Quadratech Diagnostics Limited is a corporate member of the Institute of Biomedical Scientists (IBMS) and the British Society for Haemostasis and Thrombosis (BSHT). We are a recognised supplier to the UK National Health Service (NHS), the Irish Health Service Executive (HSE), private laboratories, the UK pharmaceutical industry, and university research groups. Quadratech Diagnostics Limited became incorporated as a limited company in 1998 and is ISO 9001:2015 certified.

Our Product Brands

Latest News

Quadratech Diagnostics launches Factor-X Activator RVV-X globally

We are delighted to announce a global launch of Factor-X Activator RVV-X (50U) as the latest addition to the Q-TOX range of high quality toxins, antigens, antibodies, and virus-like particles (VLPs). Q-TOX RVV-X is a highly purified Factor X activating enzyme prepared from the Russell Viper Venom (Daboia russelii). Q-TOX RVV-X is available for research […]

Haemostasis January 2025 Journal Club

Keep informed about evolving science and clinical practice with our January 2025 compilation of the latest studies, guidelines, and perspectives in haemostasis. PERSPECTIVES & REVIEWS Albert CM. Oral anticoagulation in device patients with atrial high-rate episodes: Shared decision-making after ARTESIA and NOAH-AFNET-6. Circulation. 2024;150(18):1398-1400. doi:10.1161/CIRCULATIONAHA.124.068018 Bos MHA, van Diest RE, Monroe DM. Blood coagulation factor […]

Haemostasis November & December 2024 Industry News

Our round-up of the latest developments from across the haemostasis industry for November & December 2024, including key readouts at ASH2024 REGULATORY Vaderis Therapeutics’ VAD044 (AKT inhibitor) granted FDA Fast Track designation for the treatment of Hereditary Haemorrhagic Telangiectasia (HHT) (18 Nov) Kedrion Biopharma announced that the FDA approved the company’s manufacturing facility in Bolognana, […]

Our Accreditations

Cookie Consent

Cookies help us deliver our services. By using our services, you agree to our use of cookies.